# A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Study · id `cardio:ct-nct07668336` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07668336](<https://clinicaltrials.gov/study/NCT07668336>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07668336

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 170 participants.

## Technical summary

Registry record NCT07668336. Randomized; no masking; primary purpose treatment. Start 2026-07-08 (actual); primary completion 2030-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 170 participants (planned count; ClinicalTrials.gov record NCT07668336, source copy `cardio:ctgov-nct07668336-2026-11-05`, retrieved 2026-11-18)
- Started: 2026-07-08 (actual) (ClinicalTrials.gov record NCT07668336, source copy `cardio:ctgov-nct07668336-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2030-03 (anticipated) (ClinicalTrials.gov record NCT07668336, source copy `cardio:ctgov-nct07668336-2026-11-05`, retrieved 2026-11-18)
- Completion: 2030-03 (anticipated) (ClinicalTrials.gov record NCT07668336, source copy `cardio:ctgov-nct07668336-2026-11-05`, retrieved 2026-11-18)
- Countries: United States; Belgium; Brazil; India; Italy; Japan; Mexico; South Korea; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT07668336, source copy `cardio:ctgov-nct07668336-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07668336-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
- Acronym: ACHIEVE-PEDS
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Orforglipron
- Intervention (Drug): Dulaglutide
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: dccb2c56f320e109c7dede46ac05716d1e7ea0f7c3e8066d7190290a3df47c5b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
